Home
About
Overview
Sharing Data
ORCID
Help
History (9)
UPR(mt)-mediated cytoprotection and organismal aging.
Overview of guide RNA design tools for CRISPR-Cas9 genome editing technology
Perinatal substance use: a prospective evaluation of abstinence and relapse.
Changing Severity and Epidemiology of Adults Hospitalized With Coronavirus Disease 2019 (COVID-19) in the United States After Introduction of COVID-19 Vaccines, March 2021-August 2022.
Immunotherapy for head and neck cancer: where do we go from here?
See All 9 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Immunotherapy for head and neck cancer: where do we go from here?
Ko EC, Hanna GJ. Immunotherapy for head and neck cancer: where do we go from here? Immunotherapy. 2023 12; 15(18):1497-1500.
View in:
PubMed
subject areas
Combined Modality Therapy
Head and Neck Neoplasms
Humans
Immunotherapy
Patient Selection